Clinical and transplant characteristics of sequential patients aged 60 and above, separated into 3 groups by size of CH clone
| Characteristic . | All (n = 97) . | No CH (n = 37) . | CH positive VAF 1%-10% (n = 48) . | CH positive VAF | P value . |
|---|---|---|---|---|---|
| Median age (range) | 67 (60-78) | 65 (60-77) | 68 (60-78) | 70 (61-75) | .04 |
| Male sex | 62 (64%) | 24 (65%) | 31 (65%) | 7 (58%) | .9 |
| Graft source | .7 | ||||
| PB | 26 (28%) | 8 (22%) | 15 (31%) | 3 (25%) | |
| BM | 71 (72%) | 29 (78%) | 33 (69%) | 9 (75%) | |
| Match | .6 | ||||
| Haploidentical | 85 (88%) | 30 (81%) | 44 (92%) | 11 (92%) | |
| Full (inc 9/10) | 5 (5%) | 3 (8%) | 2 (4%) | 0 | |
| mMUD | 7 (7%) | 4 (11%) | 2 (4%) | 1 (8%) | |
| HCT-CI, med (range) | 1 (0-7) | 1 (0-6) | 1 (0-7) | 1 (0-4) | .9 |
| 0 | 27 (28%) | 12 (32%) | 13 (27%) | 2 (17%) | .9 |
| 1 to 2 | 48 (49%) | 17 (46%) | 24 (50%) | 7 (58%) | |
| 3+ | 22 (23%) | 8 (22%) | 11 (23%) | 3 (25%) | |
| Disease | .56 | ||||
| T ALL | 2 | 0 | 2 | 0 | |
| Ph+ B ALL | 6 | 2 | 4 | 0 | |
| Ph- ALL | 3 | 1 | 1 | 1 | |
| T-PLL | 2 | 1 | 1 | 0 | |
| T-cell lymphoma | 11 | 5 | 4 | 2 | |
| CLL | 3 | 0 | 1 | 2 | |
| B-cell lymphoma∗ | 64 | 25 | 32 | 7 | |
| HL | 6 | 3 | 3 | 0 | |
| Disease risk index | .6 | ||||
| Low | 28 | 11 | 14 | 3 | |
| Intermediate | 65 | 25 | 32 | 8 | |
| High/very high | 4 | 0 | 2 | 1 | |
| Lines of cytotoxic chemotherapy | .65 | ||||
| 0 | 5 (5%) | 2 (5%) | 2 (4%) | 1 (8%) | |
| 1 | 25 (26%) | 8 (22%) | 14 (29%) | 3 (25%) | |
| 2 | 49 (51%) | 23 (62%) | 20 (42%) | 6 (50%) | |
| 3 | 16 (16%) | 4 (11%) | 10 (21%) | 2 (17%) | |
| 4 | 2 (2%) | 0 | 2 (4%) | 0 | |
| Donor age, median (range) | 31 (14-54) | 29 (16-50) | 32 (14-49) | 37 (26-54) | .11 |
| Characteristic . | All (n = 97) . | No CH (n = 37) . | CH positive VAF 1%-10% (n = 48) . | CH positive VAF | P value . |
|---|---|---|---|---|---|
| Median age (range) | 67 (60-78) | 65 (60-77) | 68 (60-78) | 70 (61-75) | .04 |
| Male sex | 62 (64%) | 24 (65%) | 31 (65%) | 7 (58%) | .9 |
| Graft source | .7 | ||||
| PB | 26 (28%) | 8 (22%) | 15 (31%) | 3 (25%) | |
| BM | 71 (72%) | 29 (78%) | 33 (69%) | 9 (75%) | |
| Match | .6 | ||||
| Haploidentical | 85 (88%) | 30 (81%) | 44 (92%) | 11 (92%) | |
| Full (inc 9/10) | 5 (5%) | 3 (8%) | 2 (4%) | 0 | |
| mMUD | 7 (7%) | 4 (11%) | 2 (4%) | 1 (8%) | |
| HCT-CI, med (range) | 1 (0-7) | 1 (0-6) | 1 (0-7) | 1 (0-4) | .9 |
| 0 | 27 (28%) | 12 (32%) | 13 (27%) | 2 (17%) | .9 |
| 1 to 2 | 48 (49%) | 17 (46%) | 24 (50%) | 7 (58%) | |
| 3+ | 22 (23%) | 8 (22%) | 11 (23%) | 3 (25%) | |
| Disease | .56 | ||||
| T ALL | 2 | 0 | 2 | 0 | |
| Ph+ B ALL | 6 | 2 | 4 | 0 | |
| Ph- ALL | 3 | 1 | 1 | 1 | |
| T-PLL | 2 | 1 | 1 | 0 | |
| T-cell lymphoma | 11 | 5 | 4 | 2 | |
| CLL | 3 | 0 | 1 | 2 | |
| B-cell lymphoma∗ | 64 | 25 | 32 | 7 | |
| HL | 6 | 3 | 3 | 0 | |
| Disease risk index | .6 | ||||
| Low | 28 | 11 | 14 | 3 | |
| Intermediate | 65 | 25 | 32 | 8 | |
| High/very high | 4 | 0 | 2 | 1 | |
| Lines of cytotoxic chemotherapy | .65 | ||||
| 0 | 5 (5%) | 2 (5%) | 2 (4%) | 1 (8%) | |
| 1 | 25 (26%) | 8 (22%) | 14 (29%) | 3 (25%) | |
| 2 | 49 (51%) | 23 (62%) | 20 (42%) | 6 (50%) | |
| 3 | 16 (16%) | 4 (11%) | 10 (21%) | 2 (17%) | |
| 4 | 2 (2%) | 0 | 2 (4%) | 0 | |
| Donor age, median (range) | 31 (14-54) | 29 (16-50) | 32 (14-49) | 37 (26-54) | .11 |
ALL, acute lymphoblastic leukemia; BM, bone marrow; HL, Hodgkin lymphoma; inc, including; mMUD, mismatched unrelated donor; NHL, non-Hodgkin lymphoma.
Includes 1 patient with multiple myeloma (small CH) and 1 patient with plasmablastic lymphoma (no CH).